Importantly, the PSMA is overexpressed on prostate cancercells and the enzyme thus attracts significant attention as a targetfor the delivery of imaging and therapeutic agents and continues toserve as an important biomarker of prostate cancer.8 Furthermore, the inhibition of PSMA in the nervous systemhas been shown to attenuate neurotoxicity associated with enhancedglutamate transmission and PSMA-specific inhibitors have demonstratedefficacy in multiple preclinical animal models, including neuropathicand inflammatory pain, traumatic brain injury, stroke, and amyotrophiclateral sclerosis.9,10. The gene discussed is FOLH1; the disease is prostate cancer.